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Abstract 
At the Canadian Testis Cancer Workshop, the rationale and feasibility of regionalization of 
testis cancer care were discussed. The two-day workshop involved urologists, medical and 
radiation oncologists, pathologists, radiologists, physician’s assistants, residents and fellows, 
and nurses, as well as patients and patient advocacy groups.   
This review summarizes the discussion and recommendations of one of the central 
topics of the workshop — the centralization of testis cancer in Canada. It was acknowledged 
that non-guideline-concordant care in testis cancer occurs frequently, in the range of 18–30%. 
The National Health Service in the U.K. stipulates various testis cancer care modalities be 
delivered through supra-regional network. All cases are reviewed at a multidisciplinary team 
meeting and aspects of care can be delivered locally through the network. In Germany, no 
such network exists, but an insurance-supported online second opinion network was 
developed that currently achieves expert case review in over 30% of cases. There are clear 
benefits to regionalization in terms of survival, treatment morbidity, and cost. There was 
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agreement at the workshop that a structured pathway for diagnosis and treatment of testis 
cancer patients is required.  
Regionalization may be challenging in Canada because of geography; independent 
administration of healthcare by each province; physicians fearing loss of autonomy and 
revenue; patient unwillingness to travel long distances from home; and the inability of the 
larger centers to handle the ensuing increase in volume. We feel the first step is to identify the 
key performance indicators and quality metrics to track the quality of care received. After 
identifying these metrics, implementation of a “networks of excellence” model, similar to that 
seen in sarcoma care in Ontario, could be effective, coupled with increased use of health 
technology, such as virtual clinics and telemedicine. 
 
 
 
Introduction 
Testis cancer is the most common solid organ cancer in men aged 15-29 years with an 
estimated 1,100 men diagnosed annually in Canada. Between 60-80% of testis cancers 
present as clinical stage 1 (organ confined) disease and the 5-year survival from testis cancer 
in Canada is 96% [1]. 
The 1st Canadian Testis Cancer Consensus Conference in 2007 resulted in the 
Canadian consensus guideline, published in 2010 which gave direction on the diagnosis and 
multidisciplinary management of testis cancer [2]. Although the terminology ‘regionalization 
of care’ was not directly used, one of the emerging themes of the first Conference and 
guideline was the importance of testis cancer care occurring at centres with volume and 
experience.  
In November 2018, we convened the 2nd Canadian Testis Cancer Workshop. This 
two-day meeting was attended by urologists, medical and radiation oncologists, pathologists, 
radiologists, physician’s assistants, residents and fellows, nurses, patients and patient 
advocacy groups – all with an interest in testis cancer. The rationale for regionalization of 
testis cancer care in Canada was the one of the lead topics with the following questions 
addressed. 
How often does testis cancer patient care deviate from published guidelines? 
The management of testis cancer patients requires a concerted multidisciplinary approach. 
Despite regularly updated guidelines regarding the management of testis cancer [2-4], non-
guideline-based care occurs. Paffenholtz demonstrated that 18% of patients at a German 
centre received non-guideline concordant treatment including under-treatment (due to missed 
chemotherapy cycles) which negatively impacted relapse free survival rates [5]. Similarly, 
non-guideline directed care was demonstrated in 30% of patients at three referral centres in 
the United States leading to delayed definitive therapy, unnecessary morbidity associated 
with overtreatment and higher rates of relapse [6]. 
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What is regionalization? 
There is no consensus definition of regionalization. It involves the integrated organization of 
a health-care system possessing multiple coordinated functions and serving a limited 
geographical territory. Three main features have been described: coordination, de-
centralization and rationalization of resources [7].   
A recent systematic review of the centralization of care for genitourinary 
malignancies by high-volume providers was associated with greater utilization of cancer 
surgery, lower morbidity, and better survival outcomes [8]. Centralization of care for testis 
cancer patients has yielded favorable outcomes according to SWENOTECA (Swedish and 
Norwegian Testicular Cancer group) and DATECA (Danish Testicular Cancer group) [9,10]. 
The low population density, public health care system, and rarity of testis cancer in 
Scandinavia mean that centralization is feasible.  
In the US, Macleod et al., in an analysis of the National Cancer Database, demonstrated that 
regionalization of testis cancer was associated with decreased diagnostic delays, earlier stage 
at diagnosis and improved survival [11].  
Currently in Canada, although there are consensus guidelines regarding the management of 
testis cancer, there is no defined regionalization of care. The challenge remains as to whether 
regionalization is possible, who would benefit from it and how to provide this service.  
What happens currently in other jurisdictions? 
The National Health Service (NHS) in the UK is a similar publicly funded single payer health 
service although Canada providers are usually private. In 2002, the National Institution for 
Clinical Excellence (NICE) released a manual ‘Improving outcomes in urological cancers’. 
They recommended the development of networks to provide and co-ordinate a wide range of 
services for patients with urological cancers within a defined geographical area. Different 
degrees of specialization were required to deal with the various types of cancer, and 
multidisciplinary teams (MDTs) were recommended to be established in cancer units, cancer 
centres, and at the supra-network level [12].  
Professor Robert Huddart, Clinical Oncologist at the Royal Marsden Hospital in 
London described the testis cancer network they provide for South-East of London with a 
catchment population of ~5million. There are ~15-20 such testis cancer centres in the UK, 
each managing about 100 new cases per year. These are divided into local, regional and 
supra-regional centres to provide multidisciplinary care for patients at all points in their testis 
cancer journey. The MDT consists of at least two urologists, a clinical oncologist, a medical 
oncologist, a specialized radiologist and pathologist, clinical nurse specialist and an MDT co-
ordinator. There is a weekly MDT meeting in which all new cases and recurrent patients are 
discussed. The NICE guideline stipulates the initial diagnosis and management (radical 
orchiectomy) can be provided locally and then referral to the testis cancer network within 24 
hours after surgery unless there is evidence of de novo metastatic disease.  
Professor Peter Albers discussed the management of testis cancer in Germany where there is 
a similar lack of regionalization as in Canada. Since 2006, however, a unique online second 
opinion network was developed to allow urologists to seek expert opinion from a designated 
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second opinion provider. Professor Albers reported data from the network demonstrating 
discordance between the primary and expert opinion in up to 39.5% of cases (even in clinical 
stage 1) with a change in treatment plan in 17.3% [13]. Thus, nearly 1 in 5 new testis cancer 
cases benefited from having their case reviewed at the second opinion network.  This system 
has since become funded by insurance companies for the primary physician which 
incentivizes an expert opinion and it currently captures ~ 30% of new cases.  
In November 2016, the European Society for Medical Oncology convened a testis 
cancer consensus conference. One of their key recommendations was that outside of an 
orchiectomy, treatment of patients with testis cancer should be conducted in high volume 
centres [14]. They advocated the benefits of centralized care to include a pathological review 
of orchiectomy or other tissue material when needed, specialist radiological evaluation at 
diagnosis, post-chemotherapy, and during follow-up, guideline-based indication and delivery 
of chemotherapy and surgery by expert teams, all of which might be crucial for success. 
  
What are the benefits to regionalization of testis cancer? 
The treatment of metastatic testis cancer at lower volume centres has been associated with 
poor survival [15]. Reasons for this survival difference are multifactorial and span issues with 
chemotherapy and radiotherapy delivery, surgery and perioperative care, pathology and 
radiology expertise, and supportive care. Both over-treatment and under-treatment are 
prevalent. Wymer et al reported poor adherence to NCCN guidelines at three established 
referral institutions in the US. Non-guideline directed care was identified in 30% patients. 
Over-treatment (40%) was one of the most common reasons for discordant care, though 
under-treatment (16%) occurred frequently as well. Adherence to guidelines may translate 
into improved relapse rates and survival [6], but it is important to note that benefits of 
regionalization may manifest not only in minimizing over- or under-treatment. Given the 
young age of testis cancer patients and the excellent survival, it is appropriate to focus efforts 
and resources to ensure quality of life is optimized by minimizing over- or under treatment.  
Retroperitoneal lymph node dissection (RPLND) is a complex and nuanced surgery, with a 
possibility for high morbidity/mortality. Surgery performed at a high volume centre of 
excellence has well established benefits. Capitanio compared post-chemotherapy (pcRPLND) 
performed at Indiana University (a recognized high volume testis center) to pcRPLND 
performed elsewhere (as captured by the Surveillance, Epidemiology and End Results-SEER 
database). The perioperative mortality rate for a pcRPLND at Indiana University was 0.8% 
compared with 6% in the SEER database [16]. Similar differences were noted in France, 
where pcRPLND performed by a single high-volume surgeon was compared to 66 low 
volume surgeons. There were differences in peri-operative mortality (7% vs 16%), negative 
margins (93% vs 75%) and recurrence rates (7% vs 16%) [17]. Hospital volume was also 
associated with improved survival in Japan, suggesting it was not just about surgical 
experience but also experience in all team members and infrastructure involved in peri-
operative care [18]. 
The nuances of chemotherapy with different regimes and dose intensity for risk strata 
have significant implications with respect to the morbidity and prognosis [19]. The long-term 
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effects of chemotherapy increase proportionally with the number of cycles given [20,21] 
which hypothetically may be improved with standardization of care. The SWENOTECA 
group demonstrated a risk-adapted approach to chemotherapy in NSGCT patients to maintain 
oncological outcomes while minimizing toxicity of over treatment [22,23]. Regionalization of 
care will allow dedicated centres to recommend the most appropriate chemotherapy regimen 
for patients.  
There are also economic benefits to guideline concordant care. In the short-term, 
choosing and administering a treatment with the least complications can influence care cost 
dramatically. For example, re-admissions after surgery, in-patient stays to manage 
chemotherapy-related complications, unnecessary courses of radiation, and over-imaging on 
surveillance could manifest in increased costs in the short-term [16,17,24]. In the longer-
term, treatment-related complications can lead to a life-time of increased medical expense. 
The increased risk of heart disease, second malignancies and metabolic syndrome associated 
with chemotherapy and radiotherapy mean that decisions regarding which treatments and 
number of cycles have large cost-implications 30 and 40 years later [24].  
Is regionalization possible in Canada? 
The consensus was ‘yes’, regionalization is possible. For example, in Ontario, Canada’s 
largest province by population, Cancer Care Ontario (CCO) has been successful in 
regionalizing the care of several cancers. Thoracic surgery for esophageal cancer and lung 
cancer is an example. An expert panel was convened by CCO in 2004 with the aims to 
maintain the high quality of care in current centers of excellence, to strengthen care in newly 
designated centers, and to encourage discontinuation of thoracic surgical procedures in 
centers not meeting the predefined standards [25]. The objective of regionalization was to 
achieve 90% compliance of pulmonary and esophageal cancer resections being performed in 
designated centers by the end of 2010.  
In their report, they designated centers and outlined certain standards such as number 
of surgeons, volume per center and defined performance measures such as perioperative 
mortality and wait times. A database was also developed to analyze their performance. 
Before regionalization (2004), 46 hospitals performed thoracic surgical procedures. By 2010, 
13 tertiary and 2 secondary (a centre with a formal referral pathway to a tertiary centre) 
centers were designated to perform thoracic surgery and in the final year of the analysis 
(2009-2010) 89% esophagectomies and 94% of lung resections were being performed in the 
designated centres. Regionalization achieved a significant reduction in 30-day mortality for 
pneumonectomy but no change for esophagectomy or lobectomy [26]. Regionalization of 
care in Ontario has also been addressed to varying degrees in the fields of sarcoma, lung 
cancer [27], pancreatic cancer [28], cardiac surgery [29] and palliative care [30]. British 
Columbia has adopted similar regionalization for example in trauma care [31] and a home 
oxygen program [32]. 
The management of sarcoma in Ontario has been one of the successful 
implementations of regionalization. Quality sarcoma care includes pathology review at the 
Host Centre by pathologists with a specialty or special interest in sarcoma, molecular 
diagnostics, site specific imaging, advanced limb salvage and abdominal surgery, high 
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precision radiotherapy, and the delivery of  chemotherapy regimens. In Ontario, sarcoma 
services are organized through three multi-regional collaborative sarcoma programs, centered 
in Toronto, Hamilton and Ottawa [33]. Each program has a Host Site which provides a full 
spectrum of specialized sarcoma services. Partner Sites and hospitals in Partner Regions 
provide a sub-set of services appropriate to their level of expertise and under stewardship of 
the Host Site. The Partner Centre is involved with the diagnosis but must receive a central 
pathology review. They can also provide radiation treatment, non-complex surgery and 
adjuvant chemotherapy after discussion with the host site. The other centres in the Partner 
Region are involved with diagnostic imaging, delivery of chemotherapy, palliative 
radiotherapy and rehabilitation. The purpose of this provincial sarcoma plan is to provide all 
patients in Ontario, no matter where they reside, access to comprehensive sarcoma services. 
CCO has recently published a report on complex surgery in the retroperitoneum (RPLND) 
[34]. One of their recommendations is that patients should be referred to higher volume 
centres for resection.  
What is Canada’s challenge in regionalization? 
Canada has numerous obstacles to regionalization – some are unique to Canada, while others 
are shared with countries that have successfully implemented forms of regionalization. The 
barriers include: a) vast geography; b) independent and siloed administration of healthcare by 
each province; c) physician/provider fear of loss of autonomy and revenue; d) patient 
unwillingness or inability to travel long distances from home for assessment and treatment; e) 
inability of the large centres to handle the ensuing increase in volume; and f) the formidable 
capital investment that would be required to implement organization and infrastructure for 
regionalization (e.g. patient navigators, coordinators, e-health systems etc.) in a system that is 
currently cash-strapped. 
Canada is the second largest country in land mass in the world, yet ranks 38th in 
population. This translates into a population density that ranks 230th. Immediately one can see 
how geography is a formidable challenge to regionalization compared to Scandinavia, the UK 
or Germany, where aspects of regionalization have been well adopted, Table 1.  
The Atlantic Provinces, which includes New Brunswick, Nova Scotia, Prince Edward Island, 
and Newfoundland and Labrador were discussed as an example. It has a population of 
approximately 2.4 million people with 60 new testis cancer cases per year. By comparison 
this is half the number of new cases per year seen by the Royal Marsden Cancer Centre 
Network in London described by Professor Huddart. Geographically, however the land mass 
of the Atlantic Provinces is equivalent to the UK and Germany combined. The Canadian 
challenge is how to provide the highest level of cancer care to 60 patients across 4 vast 
provinces with a 40-50% rural population and the lowest yearly incomes in Canada.  
A regionalization policy where all testis cancer patients in Atlantic Canada are seen, 
treated and followed in Halifax (the largest city in Atlantic Canada) is not feasible. A 
Canadian solution of ‘Networks of Excellence’ was proposed as opposed to ‘Centres of 
Excellence’. A regional or provincial coordinated patient centered approach may be feasible. 
Patients could be diagnosed, treated and followed locally in the community by urologists and 
oncologists with care directed by the regional center. The development of a multi-disciplinary 
CUAJ – Review                                             Nason et al                        
Regionalization of testis cancer 
 
7 
© 2020 Canadian Urological Association 
forum with a coordinator would be key. All cases could be presented and discussed centrally 
through the MDT coordinator, with expert testis pathology and radiology review. This would 
support physicians in smaller centers to continue to manage certain predefined (Clinical Stage 
1 or good risk) patients locally. Metastatic Intermediate/poor risk, salvage or those requiring 
RPLND would ideally be treated at the designated regional center (Halifax for Atlantic 
Canada) and if not possible, at the designated provincial center. 
Developments to improve the quality of care to patients who live remotely could 
include the development of virtual clinics. For example, Dr. Robert Hamilton is the principal 
investigator of a virtual clinic trial at the Princess Margaret Cancer Centre in which testicular 
cancer patients with Clinical Stage 1 disease are randomized to standard of care in-person 
visits, or virtual assessments [35]. Patients in the virtual arm follow the standard Princess 
Margaret surveillance schedule however instead of an in person clinic visit, they interact 
asynchronously with their physician through a custom-designed online module. The study is 
currently accruing with safety, feasibility and cost-metrics with planned report out in 2 years. 
There is concern that regionalization will further marginalize patients who live in 
remote locations. However, this is not supported by the evidence. For example, Lorree et al. 
demonstrated no correlation between distance (>100km from referral centre) or community 
size and receipt of treatment modality in rectal cancer in British Columbia [36]. Similarly, 
Canale et al, demonstrated no correlation between rurality and outcomes in advanced 
pancreatic cancer in British Columbia [37]. In bladder cancer, a multicenter study across the 
United States and Canada observed distance travelled to the treatment facility was not 
associated with 90-day mortality, cancer-specific or all-cause mortality [38] following 
cystectomy. These studies suggest that the travel distance is not a barrier to appropriate 
oncologic care at regional tertiary care centers. 
No doubt the need to travel to a referral centre adds a further burden to patients and 
their families. However, Shalowitz et al. highlighted that 80% of patients are willing to travel 
to a referral centre when made aware of the improved survival advantage in ovarian cancer 
[39]. Interestingly, Wong et al demonstrated that distance travelled was one of the least likely 
factors to influence a patient’s preference regarding decisions for cancer care in Australia 
[40]. Resio et al demonstrated that the most common factor making patients reluctant to 
travel for treatment was the associated cost and that 94% would travel if the financial burden 
was adjusted (transport, parking, hotel)- many of which are already accounted for in travel 
grants in Ontario and other provinces[41].  
From a physician’s perspective, regionalization can result in drain of patients away 
from local practice resulting in a reluctance of some community based physicians to support 
it. Many physicians have managed testis cancer appropriately for many years and are reticent 
to give this up. The method of reimbursement for many surgeons and physicians in Canada 
(who are mostly private practitioners) is fee for service [42]. One suggested key element is to 
engage local providers in a testis cancer network. Not all patients need to be diverted to large 
tertiary referral centres. The initial diagnosis, staging and radical orchiectomy can be offered 
locally in accordance with defined treatment pathways. The local providers can be involved 
with presenting their cases at the weekly MDT meeting. The MDT consensus can then offer a 
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treatment strategy which can, in some patients, be carried out locally. The ‘Network of 
Excellence’ model can be developed to engage local providers, to direct and facilitate patient 
care. 
Conclusions 
Care of testis cancer patients is often non-guideline concordant; this is particularly true away 
from large volume cancer centres. Such deviation from guidelines can translate into worse 
outcomes. The Canadian Testis Cancer Workshop participants agreed that a structured 
pathway for diagnosis and treatment of testis cancer patients is required. Several barriers to 
successful Canadian implementation of this were identified, with expansive geography being 
the most formidable. This prevents simply adopting systems that have been successful in 
other countries and/or health care systems.  
A Canadian specific approach to regionalization is required. We think the first step is 
to identify what the key performance indicators and quality metrics are to track the quality of 
care received. Efforts are ongoing within the Canadian testis cancer community to do this. 
After identifying these metrics, implementation of a ‘networks of excellence’ model, similar 
to that seen in sarcoma care could be effective, coupled with increased utilization of health 
technology such as virtual clinics and telemedicine. These changes are best implemented in 
stages, but it is clear that change needs to happen.  
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Figures and Tables 
 
Table 1. Population, surface area and incidence of testis cancer
 Population Surface area New cases per 
year 
Incidence per 
100 000 
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U.K. 66.04 million 242 495 km2 2400 3.6 
Germany 82.79 million 357 386 km2 4020 4.9 
Denmark 5.75 million 42 933 km2 300 5.2 
Canada 37.06 million 9 985 000 km2 1100 2.7 
U.S. 327.2 million 9 834 000 km2 9560 2.9 
 
